Neuroprotective effect of baicalein in patients with Parkinson's disease

Zhongguo Zhongyao Zazhi

Volumn 37, Issue 4, 2012, Pages 421-425

  Yu, Xin ^b   He, Guorong ^a   Du, Guanhua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b YANTAI UNIVERSITY   (China)

Author keywords

Baicalein; Neuroprotective effect; Parkinson's disease

Indexed keywords

BAICALEIN;

HUMAN; NEUROPROTECTION; PARKINSON DISEASE; REVIEW;

FLAVANONES; HUMANS; MITOCHONDRIA; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84860897265     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20120403     Document Type: Review

References (47)

1. Lu J, Wang J S, Kong L Y. Anti-inflammatory effects of Huang-Lian-Jie-Du Decoction, its two fractions and four typical compounds[J]. J Ethnopharmacol, 2011,134(3):911.
2. Hwang J M, Tseng T H, Tsal Y Y, et al. Protective elects of baicalein on tert - butyl hydroperoxide-induced hepatic toxicity in rat hepatocytes[J]. Biomed Sci, 2005,12(2):389.
3. Dou J, Chen L, Xu G, et al. Effects of baicalein on Sendai virus in vivo are linked to serum baicalin and its inhibition of hemagglutinin- neuraminidase[J]. Arch Virol, 2011,156(5):793.
4. Yun M Y, Yang J H, Kim D K, et al. Therapeutic effects of baicalein on atopic dermatitis-like skin lesions of NC/Nga mice induced by dermatophagoides pteronyssinus[J]. Int Immunopharmacol, 2010,10(9):1142.
5. 2-induced oxidative stress by scavenging reactive oxygen species and downregulating the expression of matrix metalloproteinase-9 and vascular endothelial growth factor[J]. J Ocul Pharmacol Ther, 2010,26(5):421.
6. Van Leyen K, Kim H Y, Lee S R, et al. Baicalein and 12/15-lipoxygenase in the ischemic brain[J]. Stroke, 2006,37:3014.
7. Lebeau A, Esclaire F, Rostene W, et al. Baicalein protects cortical neurons from beta-amyloid (25-35) induced toxicity[J]. Neuroreport, 2001,12(10):2199.
8. Im H I, Joo W S, Nam E, et al. Baicalein prevents 6-hydroxydopamine- induced dopaminergic dysfunction and lipid peroxidation in mice[J]. J Pharmacol Sci, 2005,98:185.
9. Schiess M C, Barnes J L, Ellmore T M, et al. CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes[J]. Brain Res, 2010,11:151.
10. Qian L, Flood P M, Hong J S. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy[J]. J Neural Transm, 2010,117(8):971.
11. Hunot S, Hirsch E C. Neuroinflammatory processes in Parkinson's disease[J]. J Ann Neuro, 2003,53(3):492.
12. Mosley R L, Benner E J, Kadiu I, et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease[J]. Clin Neurosci Res, 2006,6(5):261.
13. Miller J A, Trout B R, Sullivan K A, et al. Low-dose 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κ reporter mice prior to loss of dopaminergic neurons[J]. J Neurosci Res, 2011,89(3):406.
14. Barnum C J, Tansey M C. Modeling neuroinflammatory pathogenesis of Parkinson's disease[J]. Prog Brain Res, 2010,184:113.
15. Miklossy J, Doudet D D, Schwab C, et al. Role of ICAM-1 in persisting inflammation in Parkinson's disease and MPTP monkeys[J]. Exp Neurol, 2006,197(2):275.
16. Hsieh C J, Hall K, Ha T, et al. Baicalein inhibits IL-1beta- and TNF-alpha-induced inflammatory cytokine production from human mast cells via regulation of the NF-kappaB pathway[J]. Clin Mol Allergy, 2007,5:5.
17. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6[J]. Biochim Biophys Acta, 2011,1813(15):878.
18. Conductier G, Blondeau N, Guyon A, et al. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases[J]. J Neuroimmunol, 2010,224(1/2):93.
19. Kaneko T, Chiba H, Horie N, et al. Effect of Scutellariae Radix ingredients on prostaglandin E(2) production and COX-2 expression by LPS-activated macrophage[J]. In Vivo, 2009,23(4):577.
20. Li F Q, Wang T, Pei Z, et al. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons[J]. J Neural Transm, 2005,12(3):331.
21. Gao Z H, Huang H, Yang X L, et al. Free radical scavenging and antionxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi[J]. Biochim Biophys Acta, 1999,1472(3):643.
22. Gao Z, Huang K, Xu H. Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in SH-SY5Y cells[J]. Pharmacol Res, 2001,43(2):173.
23. Zhang S, Ye J, Dong G. Neuroprotective effect of baicalein on hydrogen peroxide-mediated oxidative stress and mitochondrial dysfunction in PC12 cells[J]. J Mol Neurosci, 2010,40(3):311.
24. + - induced neurodegeneration[J]. J Neurochem, 2010,115(1):247.
25. Banerjee R, Starkov A A, Beal M F, et al. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis[J]. Biochim Biophys Acta, 2009,1792(7):651.
26. Haas R, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early unt reated Parkinson's disease[J]. Ann Neurol, 1995,37:714.
27. Kyung Leea, Kyoung Ah Kangb, Rui Zhangb, et al. Mitochondria protection of baicalein against oxidative damage via induction of manganese superoxide dismutase[J]. Environ Toxicol Pharmacol, 2011,31:233.
28. He X L, Wang Y H, Gao M, et al. Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage[J]. Brain Res, 2009,1249:212.
29. Bender C, Rassetto M, de Olmos J S, et al. Involvement of AMPA/kainate-excitotoxicity in MK801-induced neuronal death in the retrosplenial cortex[J]. Neuroscience, 2010,169(2):720.
30. Kim K, Lee S G, Kegelman T P, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics[J]. J Cell Physiol, 2010,226(10):2484.
31. Meredit G E, Totterdell S, Beales M, et al. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease[J]. Exp Neurol, 2009,219:334.
32. Lee H H, Yang L L, Wang C C, et al. Differential effects of natural polyphenols on neuronal survival in primary cultured central neurons against glutamate- and glucose deprivation-induced neuronal death[J]. Brain Res, 2003,986(1/2):103.
33. Ge Q F, Hu X, Ma Z Q, et al. Baicalin attenuates oxygen-glucose deprivation-induced injury via inhibiting NMDA receptor-mediated 5-lipoxygenase activation in rat cortical neurons[J]. Pharmacol Res, 2007,55(2):148.
34. Masliah E, Rockenstein E, Adame A, et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease[J]. Neuron, 2005,46(6):857.
35. Alberio T, Bossi A M, Milli A, et al. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis[JJ]. FEBS J, 2010,277(23):4909.
36. Lu J H, Ardah M T, Durairajan S S, et al. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation[J]. Chem Biochem 2011,12(4):615.
37. Jiang M, Porat-Shliom Y, Pei Z, et al. Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism[J]. J Neurochem, 2010,114(2):419.
38. Zhu M, Rajamani S, Kaylor J, et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils[J]. J Biol Chem, 2004,279(26):26846.
39. 2+ elevation by reducing phospholipase C activity in C6 rat glioma cells[J]. J Pham Pharmacol, 1998,50(10):1179.